IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $67.32 million. The enterprise value is $60.78 million.
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025, before market open.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 56.57 million shares outstanding. The number of shares has increased by 11.48% in one year.
| Current Share Class | 56.57M |
| Shares Outstanding | 56.57M |
| Shares Change (YoY) | +11.48% |
| Shares Change (QoQ) | +8.12% |
| Owned by Insiders (%) | 49.28% |
| Owned by Institutions (%) | 0.27% |
| Float | 28.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.55 |
| Forward PS | 12.78 |
| PB Ratio | 9.84 |
| P/TBV Ratio | 9.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.95, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.95 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -160.70% and return on invested capital (ROIC) is -97.51%.
| Return on Equity (ROE) | -160.70% |
| Return on Assets (ROA) | -67.69% |
| Return on Invested Capital (ROIC) | -97.51% |
| Return on Capital Employed (ROCE) | -222.26% |
| Revenue Per Employee | $49,864 |
| Profits Per Employee | -$232,091 |
| Employee Count | 66 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 0.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.46% in the last 52 weeks. The beta is 2.31, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -2.46% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 51.70 |
| Average Volume (20 Days) | 159,265 |
Short Selling Information
The latest short interest is 291,565, so 0.52% of the outstanding shares have been sold short.
| Short Interest | 291,565 |
| Short Previous Month | 285,526 |
| Short % of Shares Out | 0.52% |
| Short % of Float | 1.02% |
| Short Ratio (days to cover) | 0.83 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.29 million and -$15.32 million in losses. Loss per share was -$0.30.
| Revenue | 3.29M |
| Gross Profit | 1.45M |
| Operating Income | -15.70M |
| Pretax Income | -14.49M |
| Net Income | -15.32M |
| EBITDA | -15.36M |
| EBIT | -15.70M |
| Loss Per Share | -$0.30 |
Full Income StatementBalance Sheet
The company has $7.56 million in cash and $459,000 in debt, giving a net cash position of $7.11 million or $0.13 per share.
| Cash & Cash Equivalents | 7.56M |
| Total Debt | 459,000 |
| Net Cash | 7.11M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 6.90M |
| Book Value Per Share | 0.12 |
| Working Capital | 5.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.56 million and capital expenditures -$71,000, giving a free cash flow of -$12.63 million.
| Operating Cash Flow | -12.56M |
| Capital Expenditures | -71,000 |
| Free Cash Flow | -12.63M |
| FCF Per Share | -$0.22 |
Full Cash Flow StatementMargins
| Gross Margin | 44.09% |
| Operating Margin | -476.94% |
| Pretax Margin | -465.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.48% |
| Shareholder Yield | -11.48% |
| Earnings Yield | -22.57% |
| FCF Yield | -18.61% |
Analyst Forecast
The average price target for IceCure Medical is $2.50, which is 110.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.50 |
| Price Target Difference | 110.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 104.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IceCure Medical has an Altman Z-Score of -10.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.32 |
| Piotroski F-Score | 3 |